The Oakwood Village, Ohio-based company said it had a loss of 39 cents per share. Losses, adjusted for non-recurring costs and severance costs, came to 25 cents per share.
The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 22 cents per share.
The radiation therapy systems maker posted revenue of $17.7 million in the period, which also fell short of Street forecasts. Five analysts surveyed by Zacks expected $18.3 million.
ViewRay expects full-year revenue of $80 million.
ViewRay shares have fallen 5.5 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $8.75, a climb of slightly more than 8 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VRAY at https://www.zacks.com/ap/VRAY
Copyright 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.